Specialty Pharmaceutical Company
Curatis is a specialty pharmaceutical company based in Switzerland. We focus on the acquisition, development and commercialisation of innovative medicines for the prevention, diagnosis and treatment of rare and specialty care diseases.
Our Strategy
Curatis identifies potential drug candidates in indications with high unmet medical need via its extensive network within the scientific and medical community and the biotech/pharmaceutical industry.
Our strategy is to identify compounds for which safety and clinical efficacy data already exist, enabling faster development with lower risk and investment through to commercialization. All of Curatis' development projects have been selected in line with this strategy.
For our distribution business, Curatis acquires, licenses, distributes, and promotes medicines for the treatment and/or prevention of orphan and specialty diseases in Switzerland, with expansion into Germany, France, the UK, and Italy.
Board of Directors
Dr. Marian Borovsky
Chairman, Non-Executive Member of the Board of Directors
As Group General Counsel and a member of the Executive Committee, led Actelion's legal department for 17 years from its startup phase until its acquisition by Johnson & Johnson in 2017.
Günter Graubach
Founder & Executive Member of the Board of Directors, Chief Corporate Development Officer (CCDO)
Former Chairman of the board of directors of Curatis (2012–April 2024) and Curatis' Chief Executive Officer (until 2011).
Dr. Roland Rutschmann
Executive Member of the Board of Directors, Chief Executive Officer (CEO)
Board member of Curatis AG and former Chief Executive Officer of Curatis (2012–2019).
Dr. Silvio Inderbitzin
Non-Executive Member of the Board of Directors
Member of the Board of Directors and shareholder of Curatis. Has held multiple senior positions in the pharmaceutical industry during the last 20 years.
Executive Management
Dr. Roland Rutschmann
Chief Executive Officer (CEO)
Former board member of Curatis AG and Chief Executive Officer of Curatis AG (2011–2019).
Günter Graubach
Chief Corporate Development Officer (CCDO)
Former Chairman of the board of directors of Curatis (2012–April 2024).
François Bersier
Chief Operating Officer (COO)
Former Chief Executive Officer at Curatis AG (2019–April 2024). Previously General Manager at Alexion Pharma International.
Patrick Ramsauer
Chief Financial Officer (CFO)
CFO of Curatis and a member of the executive management team. Previously held various positions in Corporate Finance at UBS AG.
Advisory Board
Stewart Goldman, MD
Pediatric Oncology
Internationally renowned pediatric oncologist, Chair of the Department of Child Health at the University of Arizona College of Medicine.
Prof. Dr. med. Andreas Gantenbein
Neurology & Headache
Started his career as clinical research fellow in the Headache Group of Peter Goadsby at Queen Square, London.
Dr. Anthony Man
Drug Development
Originally trained in internal medicine and oncology; currently serves as independent consultant in drug development.
Prof. Dr. Arnim Pause
Biochemistry
Professor of Biochemistry at McGill University's Goodman Cancer Institute. Author of over 90 high-impact peer-reviewed publications.